IR Overview

Webcast ImageWebcast
Adaptimmune at Leerink Partners Roundtable Series: Rare Disease and Immuno-Oncology  (Live)
09/29/16 at 8:30 a.m. ET
Adaptimmune at Leerink Partners Roundtable Series: Rare Disease and Immuno-Oncology
Thursday, September 29, 2016 8:30 a.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar

Thank you for your interest in Adaptimmune. We are a leader in the TCR T-cell therapy space focused on novel cancer immunotherapy products. We utilize the body’s own machinery – the T-cell – to target and destroy cancer cells by increasing the affinity of naturally occurring T-cell receptors (TCRs). Our lead program, utilizing our NY-ESO TCR therapeutic, has a promising risk/benefit profile to date in Phase I/II trials in solid tumors and in hematologic cancer types. We continue to build a pipeline of TCR therapeutic candidates targeting a number of additional cancer targets, including our MAGE-A10 therapy which has entered initial clinical studies.

$7.120.00 (0.00%)
ADAP (American Depositary Shares)
ExchangeNASDAQ GS (US Dollar)
Volume88,483
Today's Open$7.23
Previous Close$7.12
Data as of 09/23/16 4:00 p.m.
Refresh quote
Data provided by Nasdaq. Minimum 15 minutes delayed.
Recent NewsMore >>
DateTitle 
09/19/16Adaptimmune Announces Strategic Manufacturing Agreement with PCT to Support Development of SPEAR® T-cell Therapies Towards Commercialization
PHILADELPHIA and OXFORD, United Kingdom, Sept. 19, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that it has entered into a new five-year strategic manufacturing  agreement with PCT, a Caladrius company, (“PCT”) a subsidiary of Caladrius Biosciences (Nasdaq:CLBS) for the supply of Adaptimmune’s SPEAR® T-cell therapies.  Under the contract, Adaptimmune will benefit from exclusive access to an EU and FDA compliant... 
Printer Friendly Version
09/08/16Adaptimmune to Participate in Two Upcoming Investor Conferences
PHILADELPHIA, and OXFORD, United Kingdom, Sept. 08, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in the use of TCR engineered T-cell therapy to treat cancer, today announced its participation in the following two September conferences: James Noble, Adaptimmune’s chief executive officer, will present at the 2016 Morgan Stanley Global Healthcare Conference on Tuesday September 13, 2016 at 8:00AM EDT (1:00 PM BST). The conference is being held at the Grand ... 
Printer Friendly Version
08/08/16Adaptimmune Reports Second Quarter 2016 Financial Results
- Conference call to be held today at 8:00 AM ET (1:00 PM BST) - PHILADELPHIA and OXFORD, United Kingdom, Aug. 08, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP) (“Adaptimmune” or the “Company”), a leader in T-cell therapy to treat cancer, today reported financial results for the second quarter ended June 30, 2016. Recent Corporate and Clinical Highlights: Received access to Priority Medicines (PRIME) regulatory support from the European Medicines Agency for NY-ESO... 
Printer Friendly Version
08/03/16Adaptimmune Announces Partial Clinical Hold of Planned Pivotal Study of NY-ESO SPEAR® T-cell Therapy in Myxoid Round Cell Liposarcoma
PHILADELPHIA and OXFORD, United Kingdom, Aug. 03, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy for treatment of cancer, today announced that it has received notice from the U.S. Food and Drug administration that a partial clinical hold has been placed on its planned pivotal study of NY-ESO SPEAR® T-cell therapy in myxoid round cell liposarcoma (MRCLS). This trial is not yet active at any investigational sites, and has not recruited any patient... 
Printer Friendly Version
Upcoming EventsMore >>
DateTitle
09/29/16 8:30 a.m. ET
Adaptimmune at Leerink Partners Roundtable Series: Rare Disease and Immuno-Oncology
Notice of Annual General Meeting of Adaptimmune Therapeutics plc
11.00 a.m. London time on Thursday 16 June 2016
Receive E-mail AlertsE-mail Alert Icon
Sign up to receive e-mail alerts whenever Adaptimmune posts new information to the site. Just enter your e-mail address and click Submit.